AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04769791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracuff pressure measurement
Description: intracuff pressure is measured by a pressure manometer
Study NCT03288883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photothermal Non-ablative Erbium:YAG-laser
Description: Laser treatment of the vagina for GSM
Study NCT03288883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Microablative CO2-laser
Description: Laser treatment of the vagina for GSM
Study NCT01642342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02891785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANtiPain
Description: After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
Study NCT02623231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
Study NCT01269164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure Composite Facial Transplant
Description: Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
Study NCT00333216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Description: Posterior juxtascleral administration of suspension
Study NCT00333216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 60 mg/ML
Description: Posterior juxtascleral administration of suspension
Study NCT00333216 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: Sham posterior juxtascleral administration of suspension
Study NCT02995434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe_Lucem__Seize_The_Light_VR/
Study NCT02995434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2D PC
Description: The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/
Study NCT02201758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan-enriched complex (FLC)
Description: Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
Study NCT02201758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
Study NCT03812809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711
Description: BPI-7711: 180mg, QD, oral
Study NCT02746510 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Array comparative genomic hybridization
Description: For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
Study NCT03045003 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: RESIL Intervention
Description: Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
Study NCT04788420 — intervention group
Intervention type: DRUG
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study NCT03975192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrical Nerve Field Stimulation
Description: Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
Study NCT00748748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Culturelle
Description: 10\^10 Lactobacillus rhamnosus GG per capsule
Study NCT04598490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space closure into old extraction space
Description: Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into healed bony socket
Study NCT04598490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space closure into recent extraction space
Description: Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into fresh bony socket
Study NCT00454779 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: chemotherapy arm
Study NCT00454779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: experimental arm
Study NCT00454779 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: chemotherapy arm
Study NCT00454779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: experimental arm
Study NCT00454779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: experimental arm
Study NCT02651090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Comparison of Sonazoid enhanced ultrasound to non enhanced CT
Study NCT00332709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg/day for 3 years
Study NCT00332709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg every 6 months
Study NCT02246257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Simvastatin
Description: LDL > 2.5 is treated with 40 mg
Study NCT02246257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Losartan
Description: BT > 140/90 mmHg treated with 50 mg OD
Study NCT02246257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Losartan
Description: DM BT > 130/80 mmHg treated with 50 mg OD
Study NCT02246257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Losartan
Description: Microalbuminuria (urinary albumin creatinin ratio > 30 mg) treated with 100 mg OD
Study NCT01642342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01642342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant albumin fusion protein sEphB4-HSA
Description: Given IV
Study NCT02246257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metformin
Description: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks
Study NCT02246257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Outpatient rheumatology department
Description: (4 times yearly)
Study NCT02246257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Refered to general practice
Study NCT01244256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole + Gentamicin + Beclomethasone
Description: Treatment with Clotrimazole + Gentamicin + Beclomethasone
Study NCT01244256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole + Gentamicin
Description: Treatment with Clotrimazole + Gentamicin
Study NCT03636763 — intervention group
Intervention type: DRUG
Intervention: data report
Description: the information gliptin exposure will be reported
Study NCT03995420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy (V-NeST)
Description: V-NeST is a 12-session therapy using psychological intervention principles based on Cognitive Remediation and CBT partly based in Virtual Reality.
Study NCT03995420 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.
Study NCT03995420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.
Study NCT04484493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate nasal spray
Description: dose of 2 puff in each nostril (100 µg once daily each nostril).
Study NCT05908864 — intervention group
Intervention type: DRUG
Intervention: Magnesium sulfate
Description: Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done
Study NCT00689247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: oral solution, single dose
Study NCT00689247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: iv infusion, single dose
Study NCT04918563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
Study NCT01016028 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
Study NCT01016028 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sensory Tests
Description: Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
Study NCT01016028 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
Study NCT03204539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wilate
Description: Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
Study NCT03204539 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Wilate
Description: Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
Study NCT04520464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cervical samples for identification of HR-HPV DNA via real-time PCTR.
Description: Identification of HR-HPV DNA via real-time PCTR.
Study NCT03195491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous infusion administered over 30 minutes at 240 mg
Study NCT02683967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
Study NCT05186662 — intervention group
Intervention type: OTHER
Intervention: patient education
Description: patients in experimental group were asked to join a WeChat group, which was governed by experienced gastroenterologists. Relevant knowledge of H. pylori eradication was released in the group chat irregularly. Patients in WeChat group were allowed to ask questions at any time during the whole treatment process, soon afterwards, suggestions were given.
Study NCT05186662 — intervention group
Intervention type: OTHER
Intervention: patient education
Description: Patients in the control group received verbal education and a specifically designed printout with detailed instructions.
Study NCT02478190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tight control: goal glucose 350 mg/dL or lower
Description: Goal glucose at discharge will be 350 mg/dL or less.
Study NCT04918563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine
Description: Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
Study NCT01124565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001
Description: RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
Study NCT00563147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib (AV-951) plus temsirolimus
Description: ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
Study NCT02530645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OnTrack
Study NCT02530645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study NCT02530645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing
Study NCT02478190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loose control: goal glucose 600 mg/dL or lower
Description: Goal glucose at discharge will be 600 mg/dL or less.
Study NCT03454373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive for linkage to care
Description: Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care
Study NCT00059202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses
Study NCT01734265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)
Study NCT01734265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
Study NCT01743508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol treatment by midwife
Description: Misoprostol treatment by midwife
Study NCT01743508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol treatment by midwife
Description: Misoprostol treatment by midwife
Study NCT00535054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Again
Description: Liposome Eye Spray
Study NCT03422211 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Will ask patients questions in regards to how many narcotics they have taken and what their pain level has been.
Study NCT00282048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.
Study NCT01367457 — intervention group
Intervention type: OTHER
Intervention: Temsirolimus (Non-Interventional Study)
Description: There is not any intervention in this study.
Study NCT02623231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
Study NCT02623231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
Study NCT02623231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
Study NCT02349308 — intervention group
Intervention type: DEVICE
Intervention: CentrosFLO Long Term Hemodialysis Catheter
Study NCT00760799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discectomy with anular repair
Description: Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
Study NCT00760799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discectomy with anular repair
Description: Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
Study NCT00858572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090 (ganetespib)
Description: Chemotherapy agent
Study NCT03584581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive polyphenols
Description: The amount of polyphenols to be supplied is within the ranges of absolute biosecurity food described by different authors and used in different studies.
Study NCT00905840 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Titanium Zircon implant
Description: The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing.
Study NCT00905840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Grade IV implant
Description: The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing.
Study NCT00059202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Urso
Study NCT03787030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E Acetate ointment
Description: Application of 1 ml of ointment to the distal anal canal, every 12 hours for an 8-week period.
Study NCT03787030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl trinitrate ointment
Description: Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
Study NCT04188106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Pill
Description: FDA approved starter kit of varenicline (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) followed by FDA-approved dose of varenicline (1 mg twice daily) for the remaining 11 weeks
Study NCT04188106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine Pill
Description: For the first week, participants will receive 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night for the remaining 12 weeks.
Study NCT01643005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship Strengthening HIV Prevention Intervention
Description: The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
Study NCT01643005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Program Intervention
Description: Nurturing Parenting curriculum delivered in a group format.